Fig. 5From: Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 monthsEDSS scores in the efficacy set (A) and the completed set (B), by visit Data presented are Mean (95% CI) CI, confidence interval; EDSS, Expanded Disability Status Scale; M, Month, N, number of patientsBack to article page